SCHEMBL4919320

SCHEMBL4919320

O=C(Nc1cccc2sc(Nc3ccccc3)nc12)c1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPM2A O95278 1/20 0.48
PTPN1 P18031 1/20 0.48
PTPN6 P29350 1/20 0.48
PTPN9 P43378 1/20 0.48
DUSP3 P51452 1/20 0.48
PTPN11 Q06124 1/20 0.48
LCK P06239 2/20 0.46
RXFP1 Q9HBX9 1/20 0.45
MAPT P10636 6/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
ALDH1A1 P00352 2/20 0.45
ABL1 P00519 1/20 0.45
TSHR P16473 1/20 0.45
RIN1 Q13671 1/20 0.45
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4908696 0.90 NPC1 (0.52) DUSP3LCKMAPTMEN1KMT2A
SCHEMBL4918365 0.89 KDR (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL14034418 0.87 LCK (0.46) LCKMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4918817 0.87 LCK (0.46) LCKMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL14006470 0.86 LCK (0.49) LCKRXFP1MEN1KMT2ANPC1
SCHEMBL14034255 0.85 LCK (0.45) LCKMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4915396 0.84 RXFP1 (0.48) DUSP3LCKRXFP1KMT2AGRM5
SCHEMBL4916854 0.83 LCK (0.54) LCKMAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4919383 0.83 CCNA2 (0.57) RXFP1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL4922841 0.83 CHRM4 (0.56) LCKRXFP1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US claimed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2008-11-27 US disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed
WO-2007121154-A2 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293785-A1 SUBSTITUTED BENZOTHIAZOLE KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K2 EPM2A 2311/4885PTPN1 696/4885PTPN6 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.